A methotrexate labelled dual metal oxide nanocomposite for long-lasting anti-cancer theranostics

Joyce Tang, Shehzahdi S. Moonshi, Yuao Wu, Gary Cowin, Karla X Vazquez-Prada, Andrew C. Bulmer, Hang T. Ta

Materials Today Bio · 2024 · 10 citations · 59 references

DOIFull text

Open access

Concepts

Abstract

We explored the feasibility of a self-assembled chitosan nanocomposite incorporating cerium oxide/nanoceria and superparamagnetic iron oxide nanoparticles (Chit−IOCO NPs), conjugated with methotrexate (MTX) and Cy5 dye, as an integrated cancer theranostic nanosystem (Chit-IOCO-MTX-Cy5). In this system, nanoceria serves as an anti-cancer agent, while the superparamagnetic iron oxide nanoparticles function as a negative contrast agent for MR imaging. This dual metal oxide nanocomposite is conjugated with MTX which is a structural analogue of folate, serving both as a targeting mechanism for folate receptors on cancer cells and as a chemotherapeutic drug. Chit−IOCO-MTX-Cy5 exhibited exceptional negative contrast in T2 and T2*-weighted MRI, achieving a high relaxivity of 409.5 mM⁻ 1 s⁻ 1 which is superior to clinically approved agents. The nanocomposite demonstrated both pro-oxidative and antioxidative properties, significantly increasing reactive oxygen species (ROS) production in U87MG cells (1.4-fold change), which triggered apoptosis in these cancer cells. Simultaneously, it exhibited ROS scavenging activity in non-malignant endothelial cells (0.8-fold change). Intravenous infusion of Chit-IOCO-MTX-Cy5 (5 mg/kg MTX) led to significant tumor growth inhibition, indicating a synergistic enhancement of anti-cancer effects when combining MTX and nanoceria, compared to free MTX or nanoceria without MTX conjugation. Importantly, after treatment cessation, tumors in the nanocomposite group did not re-grow, while those in the free MTX group rapidly did. In vivo MR and fluorescence imaging revealed improved uptake and retention of Chit−IOCO-MTX-Cy5 in tumors compared to nanoceria without MTX. Notably, biosafety and biochemical analyses in mice showed no significant differences between the Chit−IOCO-MTX-Cy5 treatment group and control groups. TOC Figure: Nanohybrid platform of chitosan nanocomposites comprising cerium oxide and superparamagnetic iron oxide NPs (Chit−IOCO) conjugated to methotrexate (MTX) as an integrated cancer theranostic nanosystem. In vivo MRI displayed enhanced uptake of targeted MTX conjugated NPs in tumours indicating selectivity of the nano system which resulted in significant synergistic reduction in tumour mass.

References

59